The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...

This programme is designed to advance next-generation vaccines, therapeutics, and other tools to combat Covid-19. The therapeutic, dubbed S-892216, leverages protease inhibitor technology to block ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism. Click for my ARCT stock update.

A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...

Among adults in Ravensburg, Germany, financial incentives for COVID-19 vaccination did not result in significant changes to vaccine uptake and may have inadvertently lowered community vaccination ...

The rate of antiviral prescriptions was 67% lower in pregnant than in nonpregnant women, including those with one or more high-risk underlying conditions.

A new way to neutralize coronavirus and other membrane-surrounded viruses has been discovered by researchers from the Swedish ...

When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts ...

Covid-19 is now ubiquitous – but hospitalisations ... we still need better therapeutics and vaccines, for some people at least in the future." For essential climate news and hopeful developments ...